Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company") (Nasdaq: TTPH). Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, inclusive (the "Class Period"), are encouraged to contact the Firm prior to the March 28, 2016, lead plaintiff motion deadline. If you purchased shares of Tetraphase during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at email@example.com. There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member. According to the complaint, the Company issued materially false and misleading statements to investors regarding the efficacy and safety of Eravacycline, and its capacity for approval by both the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"). If you purchased shares of Tetraphase during the Class Period, you have until March 28, 2016 to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org. This press release may constitute Attorney Advertising in some jurisdictions.